Ascribe Bio, a natural crop‑protection innovator, today announced the closing of an oversubscribed $12 million Series A financing round, co‑led by Corteva through its Corteva Catalyst platform and Acre Venture Partners. The round also attracted participation from Syngenta Group Ventures, Trailhead Capital, Silver Blue LLC, Cultivation Capital, and The Yield Lab, underscoring broad investor confidence in the company’s small‑molecule technology.
The financing will fund the upcoming commercial launch of Phytalix®, a broad‑spectrum biofungicide that harnesses soil‑microbiome small molecules to deliver disease control with the ease of use and affordability of traditional chemical products. Phytalix is positioned to enter the Brazilian market later this year, with U.S. and other markets slated for subsequent roll‑outs.
For Corteva, the $12 million investment is a modest but strategic addition to its Catalyst portfolio, reinforcing its commitment to biologicals and nature‑inspired solutions. The capital will accelerate product development, manufacturing ramp‑up, and early commercialization activities, potentially generating revenue streams in Brazil and beyond.
This transaction aligns with Corteva’s broader strategy to become a net technology seller and expand its biologicals offering, while also demonstrating the company’s willingness to support high‑potential startups that complement its core seed and crop‑protection businesses.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.